Evidence map›Paper›PMID 35625699›Full record

ReviewBiomedicines2022

SARS-CoV-2 Infection, Sex-Related Differences, and a Possible Personalized Treatment Approach with Valproic Acid: A Review.

Donatas Stakišaitis, Linas Kapočius, Angelija Valančiūtė, Ingrida Balnytė, Tomas Tamošuitis, Arūnas Vaitkevičius, Kęstutis Sužiedėlis, Daiva Urbonienė, Vacis Tatarūnas, Evelina Kilimaitė and 2 more

Open access · goldAbstract readReview
In one paragraph

Review in Biomedicines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Neurological complications caused by SARS-CoV-2.Clinical microbiology reviews · 2024
    Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Donatas StakišaitisLaboratory of Molecular Oncology, National Cancer Institute, 08660 Vilnius, Lithuania.ORCID 0000-0002-1547-7050
Linas KapočiusDepartment of Histology and Embryology, Medical Academy, Lithuanian University of Health Sciences, 44307 Kaunas, Lithuania.
Angelija ValančiūtėDepartment of Histology and Embryology, Medical Academy, Lithuanian University of Health Sciences, 44307 Kaunas, Lithuania.ORCID 0000-0003-3611-2509
Ingrida BalnytėDepartment of Histology and Embryology, Medical Academy, Lithuanian University of Health Sciences, 44307 Kaunas, Lithuania.
Tomas TamošuitisDepartment of Intensive Care Medicine, Lithuanian University of Health Sciences, 50161 Kaunas, Lithuania.ORCID 0000-0003-1019-7268
Arūnas VaitkevičiusInstitute of Clinical Medicine, Faculty of Medicine, Vilnius University Hospital Santaros Klinikos, Vilnius University, 08661 Vilnius, Lithuania.
Kęstutis SužiedėlisLaboratory of Molecular Oncology, National Cancer Institute, 08660 Vilnius, Lithuania.
Daiva UrbonienėDepartment of Laboratory Medicine, Medical Academy, Lithuanian University of Health Sciences, Eiveniu 2, 50161 Kaunas, Lithuania.ORCID 0000-0002-7920-9856
Vacis TatarūnasInstitute of Cardiology, Laboratory of Molecular Cardiology, Lithuanian University of Health Sciences, Sukileliu Ave., 50161 Kaunas, Lithuania.
Evelina KilimaitėDepartment of Histology and Embryology, Medical Academy, Lithuanian University of Health Sciences, 44307 Kaunas, Lithuania.
Dovydas GečysInstitute of Cardiology, Laboratory of Molecular Cardiology, Lithuanian University of Health Sciences, Sukileliu Ave., 50161 Kaunas, Lithuania.ORCID 0000-0002-2056-7528
Vaiva LesauskaitėInstitute of Cardiology, Laboratory of Molecular Cardiology, Lithuanian University of Health Sciences, Sukileliu Ave., 50161 Kaunas, Lithuania.ORCID 0000-0003-2736-3111
Lithuanian University of Health Sciences · LTNational Cancer Institute · LTVilnius University · LT

Funding

Lietuvos Mokslo Taryba number 13.1.1-LMT-K-718-05-0030
6 · The paper itself

Abstract

Sex differences identified in the COVID-19 pandemic are necessary to study. It is essential to investigate the efficacy of the drugs in clinical trials for the treatment of COVID-19, and to analyse the sex-related beneficial and adverse effects. The histone deacetylase inhibitor valproic acid (VPA) is a potential drug that could be adapted to prevent the progression and complications of SARS-CoV-2 infection. VPA has a history of research in the treatment of various viral infections. This article reviews the preclinical data, showing that the pharmacological impact of VPA may apply to COVID-19 pathogenetic mechanisms. VPA inhibits SARS-CoV-2 virus entry, suppresses the pro-inflammatory immune cell and cytokine response to infection, and reduces inflammatory tissue and organ damage by mechanisms that may appear to be sex-related. The antithrombotic, antiplatelet, anti-inflammatory, immunomodulatory, glucose- and testosterone-lowering in blood serum effects of VPA suggest that the drug could be promising for therapy of COVID-19. Sex-related differences in the efficacy of VPA treatment may be significant in developing a personalised treatment strategy for COVID-19.

Indexed as

clinical researchCOVID-19pre-clinical researchsex differencesvalproic acid

Identifiers

PMID35625699
PMCPMC9138665
OpenAlexW4224210759

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.